Abstracts tagged "Disease Activity"

Abstract Number: 0302 • ACR Convergence 2025
Urine Kynurenine Pathway Biomarkers Correlate with Disease Activity and Damage Core Set Measures in JDM
Shannon O'Connor¹, Hermine Brunner¹, Josh Gunn², Payam Farhadi³, Carley Phillips⁴, Lisa Rider⁵, Alexei Grom¹ and Sheila Angeles-Han⁶, ¹Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Ethos R&D, Newport, KY, ³National Institutes of Health/National Institute of Environmental Health Sciences, Bethesda, MD, ⁴Cincinnati Children's Hospital Medical Center, Cincinnati, ⁵National Institute of Environmental Health Sciences/National Institutes of Health, Environmental Autoimmunity Group, Bethesda, MD, ⁶Cincinnati Children's Hospital, Cincinnati, OH
Background/Purpose: Juvenile dermatomyositis (JDM) is an autoimmune vasculopathy affecting muscle, skin, and vasculature. Core set measures (CSM) assess disease activity and damage, and guide treatment.…
Abstract Number: 2650 • ACR Convergence 2025
LFA-REAL Outperforms SLEDAI and BILAG in Detecting Clinical Change in Lupus Activity
Alberto Nordmann-Gomes¹, Leila Khalili², Cynthia Aranow³, Meghan mackay⁴, Mimi Kim⁵, Diane Kamen⁶, Cristina Arriens⁷, Maya Souvignier⁸, Wei Tang⁹, Stephen Suh⁸, Maria Dall'Era¹⁰, Joan Merrill¹¹ and Anca Askanase², ¹Columbia University Irving Medical Center, New York, NY, ²Columbia University Medical Center, New York, NY, ³Institute of Molecular Medicine, Feinstein Institutes for Medical Research, Manhasset, NY, ⁴Feinstein Institutes for Medical Research, Manhasset, NY, ⁵Albert Einstein College of Medicine, Bronx, NY, ⁶Medical University of South Carolina, Johns Island, SC, ⁷Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁸Columbia University Irving Medical Center, New York City, NY, ⁹Westchester Medical Center, Valhalla, NY, ¹⁰Division of Rheumatology, University of California, San Francisco, CA, ¹¹Oklahoma Medical Research Foundation, Oklahoma
Background/Purpose: Disease activity measures in SLE have important limitations that restrict their performance in clinical practice and research. The Lupus Foundation of America-Rapid Evaluation of…
Abstract Number: 2332 • ACR Convergence 2025
Development and validation of a Disease Activity index for PSoriatic Arthritis based on 44 joints: DAPSA44
Dafne capelusnik¹, Clementina López Medina², Désirée Van Der Heijde³, Daniel Aletaha⁴, Josef Smolen⁵, Anna Molto⁶ and Sofia Ramiro⁷, ¹Tel Aviv Sourasky Medical Center, Ramat Gan, Israel, ²Department of Medicine, Hospital Universitario Reina Sofia, University of Cordoba, IMIBIC, Cordoba, Spain, ³Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁴Medical University Vienna, Wien, Austria, ⁵Division of Rheumatology, Department of Medicine ³, Medical University of Vienna, Vienna, Austria, Vienna, Austria, ⁶Assistance Publique Hôpitauxde Paris, Paris, France, ⁷Leiden University Medical Center, Bunde, Netherlands
Background/Purpose: Recent studies have highlighted the potential of composite scores such as the DAPSA for assessing peripheral arthritis in axSpA and pSpA. However, the swollen…
Abstract Number: 2124 • ACR Convergence 2025
Reliability and Validation of the Physician’s Global Assessment of Lung Disease (PGALD) in Systemic Juvenile Idiopathic Arthritis -Associated Lung Disease (SJIA-LD)
Eileen Rife¹, Guihua Zhai², Mekibib Altaye³, Jennifer Andringa⁴, Hermine Brunner⁵, Scott Canna⁶, Lauren Henderson⁷, Yukiko Kimura⁸, Scott Lieberman⁹, Mona Riskalla¹⁰, Tiphanie Vogel¹¹, Holly Wobma¹² and Grant Schulert⁵, ¹University of Alabama at Birmingham, birmingham, AL, ²UAB, Birmingham, ³Cincinnati Children's Hospital, Cincinnati, ⁴Cincinnati Children's Hospital Medical Center, Cincinnati, ⁵Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁶Children's Hospital of Philadelphia, Philadelphia, PA, ⁷Boston Children's Hospital, Watertown, MA, ⁸Hackensack Meridian School of Medicine, New York, NY, ⁹University of Iowa, Iowa City, IA, ¹⁰University of Minnesota Masonic Children's Hospital, Minneapolis, MN, ¹¹Baylor College of Medicine, Houston, TX, ¹²Boston Children's Hospital, Boston, MA
Background/Purpose: The physician global assessment of lung disease (PGALD) is a recently proposed disease activity measure for patients with systemic juvenile idiopathic arthritis-associated lung disease…
Abstract Number: 1536 • ACR Convergence 2025
Evaluating Systemic Lupus Erythematosus Remission Among Patients Initiating Belimumab in a Real-World Setting in the USA
Aarat M Patel¹, Renee L. Gennarelli², Temitope Bello², Ali Bonakdar² and Karen Worley³, ¹GSK, US Medical Affairs, Durham, NC, ²Cencora, Real-World Evidence, Conshohocken, PA, ³GSK, Global Real-World Evidence & Health Outcomes Research, Collegeville, PA
Background/Purpose: The Definition Of Remission In SLE (DORIS) criteria were developed to provide alignment on defining remission in patients with SLE.1,2 Belimumab (BEL) treatment increases…
Abstract Number: 1409 • ACR Convergence 2025
The impact of depression in axial spondyloarthritis: Epidemiological insights from the Ankylosing Spondylitis Registry of Ireland (ASRI)
Conall Mac Gearailt¹, Rebecca O'Farrell², Mohamed Eltahir³, Brian Hallahan³, Andrew Smyth⁴, Finbar O'Shea⁵ and Gillian Fitzgerald³, ¹Galway University Hospital, Galway, Galway, Ireland, ²Sligo University Hospital, Sligo, Ireland, ³Galway University Hospital, Galway, Ireland, ⁴University of Galway, Galway, Ireland, ⁵St James's Hospital and Trinity College Dublin, Dublin, Dublin, Ireland
Background/Purpose: The burden of comorbidities in Axial Spondyloarthritis (axSpA) is increasingly recognised and contributes to the concept of difficult-to-treat axSpA (D2T-axSpA). The need to assess…
Abstract Number: 1207 • ACR Convergence 2025
Cutaneous and Muscular Disease Trajectories in Adult Patients with Dermatomyositis
Jesus Valencia¹, Will Kelly¹, Sean Tackett², Amanda Finney¹, Jemima Albayda¹, Julie Paik³, Lisa Christopher-Stine¹ and Chris Mecoli⁴, ¹Johns Hopkins University, Baltimore, MD, ²Johns Hopkins University, Baltimore, ³Johns Hopkins Rheumatology, Baltimore, MD, ⁴Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Dermatomyositis (DM) is a rare autoimmune disease characterized by cutaneous manifestations and proximal muscle inflammation.1,2 Notably, the clinical course of muscular and cutaneous disease…
Abstract Number: 0874 • ACR Convergence 2025
Impact of Deucravacitinib on Disease Activity in Patients With Psoriatic Arthritis (PsA): Results From the Pivotal Phase 3 PsA Studies
Atul Deodhar¹, Ricardo Blanco², Arthur Kavanaugh³, Alice Gottlieb⁴, Laura Coates⁵, Christopher Ritchlin⁶, Alan Kivitz⁷, Xiaofeng Zeng⁸, Akimichi Morita⁹, Diamant Thaçi¹⁰, Stefan Varga¹¹, Kexuan Li¹¹, Ying-Ming Jou¹², Eleni Vritzali¹³ and Philip J. Mease¹⁴, ¹Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University, Portland, OR, ²Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain, ³University of California, San Diego, School of Medicine, San Diego, CA, ⁴Department of Dermatology, UT Southwestern Medical Center, Dallas, TX, ⁵Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, England, United Kingdom, ⁶University of Rochester Medical Center, Canandaigua, NY, ⁷Altoona Center for Clinical Research, Duncansville, PA, ⁸Department of Rheumatology, Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Beijing, China (People's Republic), ⁹Department of Geriatric and Environmental Dermatology, Graduate School of Medical Sciences, Nagoya City University, Nagoya, Japan, ¹⁰Institute and Comprehensive Center for Inflammation Medicine, University of Lübeck, Lübeck, Germany, ¹¹Bristol Myers Squibb, Princeton, NJ, ¹²Bristol Myers Squibb, Princeton, ¹³Bristol Myers Squibb, Boudry, Switzerland, ¹⁴Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA
Background/Purpose: The first-in-class, oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor deucravacitinib has an established clinical profile in moderate to severe plaque psoriasis with over…
Abstract Number: 0480 • ACR Convergence 2025
Efficacy and safety of tacrolimus and its serum concentration in patients with rheumatoid arthritis with inadequate response to methotrexate
Chan-Bum Choi, Hanyang University Hosptial for Rheumatic Diseases, Seoul, Republic of Korea
Background/Purpose: Addition of a biologic disease-modifying antirheumatic drug (bDMARD) or targeted synthetic DMARD (tsDMARD) is recommended in patients with rheumatoid arthritis (RA) with inadequate response…
Abstract Number: 0297 • ACR Convergence 2025
Longitudinal Serum Proteomic Profiles – A Step Closer to Personalized Monitoring in Dermatomyositis
Natasha Le Blanc¹, Marie Hudson¹, Ana Cristina Gonzalez Sanchez², Lina Marcela Diaz Gallo² and Valerie Leclair³, ¹McGill University, Montréal, QC, Canada, ²Karolinska Institutet, Stockholm, Sweden, ³McGill University, Montréal, Canada
Background/Purpose: Dermatomyositis (DM) is a multisystemic immune mediated disease presenting with heterogeneous clinical features. Disease monitoring in DM relies in part on biomarkers of muscle…
Abstract Number: 2649 • ACR Convergence 2025
Simultaneous Assessment of Complementary Lupus-Specific Immune Mediator-Informed Indexes Improves Their Ability to Concurrently Discern Current Disease Activity And Future Flare Risk In Systemic Lupus Erythematosus
Melissa Munroe¹, Derek Blankenship², Daniele DeFreese², Adrian Holloway², Bernard Rubin², Mohan Purushothaman², Wade DeJager³, Susan Macwana⁴, Joel Guthridge⁴, Stan Kamp⁴, Nancy Redinger⁴, Teresa Aberle⁴, Eliza Chakravarty⁴, Cristina Arriens⁴, Yangfen Li⁵, Hu Zeng⁵, Stephanie Dezzutti⁶, Peter Izmirly⁷, Uma Thanarajasingam⁵, Diane Kamen⁸, Jill Buyon⁹, Judith James⁴ and Eldon Jupe², ¹Oklahoma Medical Research Foundation; Progentec Diagnostics, Inc., Oklahoma City, OK, ²Progentec Diagnostics, Inc., Oklahoma City, OK, ³Oklahoma Medical Research Foundation, Oklahoma City, ⁴Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵Mayo Clinic, Rochester, MN, ⁶Medical University of South Carolina, Charleston, SC, ⁷New York University Grossman School of Medicine, New York, NY, ⁸Medical University of South Carolina, Johns Island, SC, ⁹NYU Grossman School of Medicine, New York, NY
Background/Purpose: Immune dysregulation propels systemic lupus erythematosus (SLE) pathogenesis. Capturing it as lab-based screening tests could help prioritize SLE patients for early intervention and proactive…
Abstract Number: 2322 • ACR Convergence 2025
Gender-related Differences in Peripheral and Axial Spondyloarthritis
Mehmet Tuncay Duruöz¹, Halise Hande Gezer¹, İlknur Aktaş², Servet Akar³, Nilay Şahin⁴, Özgür Akgül⁵, Sami Hizmetli⁶, Meltem Alkan Melikoğlu⁷, Umut Kalyoncu⁸, Erhan Çapkın⁹, fatma Gülçin Ural¹⁰, Figen Yılmaz¹¹, Sebnem ATAMAN¹² and İlhan Sezer¹³, ¹Marmara University Medical School PMR Department, Rheumatology Division, Istanbul, Turkey, ²Istanbul Fatih Sultan Mehmet Training and Research Hospital, PMR, Turkey, Istanbul, Turkey, ³Department of Medicine, Izmir Katip Çelebi University School of Medicine, Izmir, Turkey, ⁴Balikesir University School of Medicine, PMR, Turkey, Balıkesir, Turkey, ⁵Manisa Celal Bayar University School of Medicine, Rheumatology, Turkey, Manisa, Turkey, ⁶Sivas Cumhuriyet University School of Medine, Rheumatology, Turkey, Sivas, Turkey, ⁷Erzurum Atatürk University School of Medicine, Rheumatology, Turkey, Erzurum, Turkey, ⁸Division of Rheumatology, Department of Internal Medicine, Hacettepe University School of Medicine, Ankara, Turkey, Ankara, Turkey, ⁹Karadeniz Teknik University School of Medicine, PMR, Turkey, Trabzon, Turkey, ¹⁰Ankara Yildirim Beyazit University School of Medicine, PMR, Turkey, Ankara, Turkey, ¹¹Istanbul Sisli Etfal Training and Research Hospital, PMR, Turkey, Istanbul, Turkey, ¹²Ankara University School of Medicine, Rheumatology, Turkey, Ankara, Turkey, ¹³Akdeniz University School of Medicine, Rheumatology, Turkey, Antalya, Turkey
Background/Purpose: This study sought to compare clinical characteristics between female and male patients with spondyloarthritis (SpA) in a Turkish population.Methods: This study included 489 peripheral…
Abstract Number: 2096 • ACR Convergence 2025
Gamification and Social Incentivization to Promote Physical Activity in Adults with Knee Osteoarthritis: Results from a Multi-Site Randomized Trial
Kimberly Hayes¹, Bryant England², Katherine Wysham³, Mercedes Quinones⁴, Marianna Olave⁵, Sarah Wetzel⁶, Hannah Brubeck⁷, Rachel Gillcrist⁸, Criswell Lavery⁹, Natalie Keller¹⁰, Bibiana Ateh¹¹, Bridget Kramer², Rui Xiao⁹, Kaitian Jin⁹, Alexis Ogdie¹², Daniel K. White¹³, Tuhina Neogi¹⁴, Carla Scanzello⁹ and Joshua Baker⁹, ¹Teachers College, Columbia University, Philadelphia, PA, ²University of Nebraska Medical Center, Omaha, NE, ³VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, ⁴Washington DC VA Medical Center, Bethesda, MD, ⁵Brown University, Philadelphia, PA, ⁶Drexel University, Pittsburgh, PA, ⁷VA Puget Sound Health Care System, Seattle, WA, ⁸Dartmouth College, Lebanon, NH, ⁹University of Pennsylvania, Philadelphia, PA, ¹⁰University of Oklahoma, Philadelphia, PA, ¹¹Washington VA Medical Center, Washington, District of Columbia, ¹²Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Wilmington, DE, ¹³University of Delaware, Newark, DE, ¹⁴Boston University School of Medicine, Boston, MA
Background/Purpose: Promotion of physical activity is important in the management of knee osteoarthritis (KOA), though effective strategies for behavioral change to promote exercise are lacking.…
Abstract Number: 1533 • ACR Convergence 2025
Belimumab Is Associated with Early Improvement in Disease Activity Measures Among Patients with Systemic Lupus Erythematosus in the US
Yan Chen¹, Maral DerSarkissian¹, Shumin Rui¹, Justin Clark¹, Daniel Moldaver², Jeffrey J. Ellis³, Karen Worley³ and Aarat M Patel⁴, ¹Analysis Group, Los Angeles, CA, ²GSK, Global Real-World Evidence & Health Outcomes Research, Toronto, ON, Canada, ³GSK, Global Real-World Evidence & Health Outcomes Research, Collegeville, PA, ⁴GSK, US Medical Affairs, Durham, NC
Background/Purpose: Belimumab (BEL), a B-cell modulator mAb that selectively inhibits soluble B-lymphocyte stimulator and reduces autoreactive B cells that drive lupus disease activity, is approved…
Abstract Number: 1396 • ACR Convergence 2025
Influence of Age on Daily Impairment, Patient Empowerment, Activation and Engagement in Patients with Sjögren’s Disease
Esra Sevimli¹, Berceste Polat², Busra Sari³, Can Akmansoy², Burcu Aksoy⁴, Omur Mumcu⁵, Hatice Kalender³, Aysegul Avcu⁶, Mustafa Erdogan⁷, Nur Sisman⁸, Farida Fortune⁹, Gonca Mumcu¹⁰ and Nevsun Inanc⁷, ¹¹Institute of Health Sciences, Marmara University, Department of Health Management, Istanbul, Turkey, ²Marmara University, Faculty of Dentistry, Istanbul, Turkey, ³Institute of Health Sciences, Marmara University, Department of Health Management, Istanbul, Turkey, ⁴Istanbul University-Cerrahpasa, Institute of Postgraduate Education, Department of Health Management, Istanbul, Turkey, ⁵Yeditepe University, Faculty of Dentistry, Istanbul, Turkey, ⁶Marmara University, Istanbul, Turkey, ⁷Marmara University, School of Medicine, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ⁸Marmara University, Faculty of Health Sciences, Istanbul, Turkey, ⁹Barts and The London School of Medicine and Dentistry, Centre Immunobiology and Regenerative Medicine, Queen Mary University of London, London, United Kingdom, ¹⁰Faculty of Dentistry, Istanbul Okan University, Istanbul, Turkey
Background/Purpose: Patient-centred care and improvement of daily life are the main components in chronic disease management. The aim of the study was to determine associations…

« Previous Page
1
…
5
6
7
8
9
…
112
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].